Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns

J. S. Lambert, L. M. Mofenson, C. V. Fletcher, Jr Moye J., E. R. Stiehm, W. A. Meyer, G. J. Nemo, B. J. Mathieson, G. Hirsch, C. V. Sapan, L. M. Cummins, E. Jimenez, E. O'Neill, A. Kovacs, A. Stek

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

The pharmacokinetics and safety of hyperimmune anti-human immunodeficiency virus (HIV) intravenous immunoglobulin (HIVIG) were evaluated in the first 28 maternal-infant pairs enrolled in a randomized, intravenous immunoglobulin (IVIG)-controlled trial of HIVIG maternal-infant HIV transmission prophylaxis. Using 200 mg/kg, mean half-life and volume of distribution (V(d)) in women were 15 days and 72 mL/kg, respectively, after one and 32 days and 154 mL/kg after three monthly infusions, with stable 4 mL/kg/day clearance. Transplacental passage occurred. Newborn single-dose half-life, V(d), and clearance were 30 days, 143 mL/kg, and 4 mL/kg/day, respectively. HIVIG rapidly cleared maternal serum immune complex-dissociated p24 antigen, and plasma HIV-1 RNA levels were stable. Mild to moderate adverse clinical effects occurred in 2 of 103 maternal and 2 of 25 infant infusions. No adverse hematologic, blood chemistry, or immunologic effects were seen. HIVIG is well-tolerated in HIV-infected pregnant women and their newborns, clears antigenemia, crosses the placenta, and exhibits pharmacokinetics similar to those of other immunoglobulin preparations.

Original languageEnglish (US)
Pages (from-to)283-291
Number of pages9
JournalJournal of Infectious Diseases
Volume175
Issue number2
DOIs
StatePublished - Jan 1 1997

Fingerprint

Intravenous Immunoglobulins
Immunoglobulins
Pregnant Women
Pharmacokinetics
HIV
Newborn Infant
Safety
Mothers
Half-Life
Antigen-Antibody Complex
Placenta
HIV-1
RNA
Antigens
Serum

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. / Lambert, J. S.; Mofenson, L. M.; Fletcher, C. V.; Moye J., Jr; Stiehm, E. R.; Meyer, W. A.; Nemo, G. J.; Mathieson, B. J.; Hirsch, G.; Sapan, C. V.; Cummins, L. M.; Jimenez, E.; O'Neill, E.; Kovacs, A.; Stek, A.

In: Journal of Infectious Diseases, Vol. 175, No. 2, 01.01.1997, p. 283-291.

Research output: Contribution to journalArticle

Lambert, JS, Mofenson, LM, Fletcher, CV, Moye J., J, Stiehm, ER, Meyer, WA, Nemo, GJ, Mathieson, BJ, Hirsch, G, Sapan, CV, Cummins, LM, Jimenez, E, O'Neill, E, Kovacs, A & Stek, A 1997, 'Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns', Journal of Infectious Diseases, vol. 175, no. 2, pp. 283-291. https://doi.org/10.1093/infdis/175.2.283
Lambert, J. S. ; Mofenson, L. M. ; Fletcher, C. V. ; Moye J., Jr ; Stiehm, E. R. ; Meyer, W. A. ; Nemo, G. J. ; Mathieson, B. J. ; Hirsch, G. ; Sapan, C. V. ; Cummins, L. M. ; Jimenez, E. ; O'Neill, E. ; Kovacs, A. ; Stek, A. / Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. In: Journal of Infectious Diseases. 1997 ; Vol. 175, No. 2. pp. 283-291.
@article{e6bb3198001546768f3f12f5723a47b8,
title = "Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns",
abstract = "The pharmacokinetics and safety of hyperimmune anti-human immunodeficiency virus (HIV) intravenous immunoglobulin (HIVIG) were evaluated in the first 28 maternal-infant pairs enrolled in a randomized, intravenous immunoglobulin (IVIG)-controlled trial of HIVIG maternal-infant HIV transmission prophylaxis. Using 200 mg/kg, mean half-life and volume of distribution (V(d)) in women were 15 days and 72 mL/kg, respectively, after one and 32 days and 154 mL/kg after three monthly infusions, with stable 4 mL/kg/day clearance. Transplacental passage occurred. Newborn single-dose half-life, V(d), and clearance were 30 days, 143 mL/kg, and 4 mL/kg/day, respectively. HIVIG rapidly cleared maternal serum immune complex-dissociated p24 antigen, and plasma HIV-1 RNA levels were stable. Mild to moderate adverse clinical effects occurred in 2 of 103 maternal and 2 of 25 infant infusions. No adverse hematologic, blood chemistry, or immunologic effects were seen. HIVIG is well-tolerated in HIV-infected pregnant women and their newborns, clears antigenemia, crosses the placenta, and exhibits pharmacokinetics similar to those of other immunoglobulin preparations.",
author = "Lambert, {J. S.} and Mofenson, {L. M.} and Fletcher, {C. V.} and {Moye J.}, Jr and Stiehm, {E. R.} and Meyer, {W. A.} and Nemo, {G. J.} and Mathieson, {B. J.} and G. Hirsch and Sapan, {C. V.} and Cummins, {L. M.} and E. Jimenez and E. O'Neill and A. Kovacs and A. Stek",
year = "1997",
month = "1",
day = "1",
doi = "10.1093/infdis/175.2.283",
language = "English (US)",
volume = "175",
pages = "283--291",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns

AU - Lambert, J. S.

AU - Mofenson, L. M.

AU - Fletcher, C. V.

AU - Moye J., Jr

AU - Stiehm, E. R.

AU - Meyer, W. A.

AU - Nemo, G. J.

AU - Mathieson, B. J.

AU - Hirsch, G.

AU - Sapan, C. V.

AU - Cummins, L. M.

AU - Jimenez, E.

AU - O'Neill, E.

AU - Kovacs, A.

AU - Stek, A.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - The pharmacokinetics and safety of hyperimmune anti-human immunodeficiency virus (HIV) intravenous immunoglobulin (HIVIG) were evaluated in the first 28 maternal-infant pairs enrolled in a randomized, intravenous immunoglobulin (IVIG)-controlled trial of HIVIG maternal-infant HIV transmission prophylaxis. Using 200 mg/kg, mean half-life and volume of distribution (V(d)) in women were 15 days and 72 mL/kg, respectively, after one and 32 days and 154 mL/kg after three monthly infusions, with stable 4 mL/kg/day clearance. Transplacental passage occurred. Newborn single-dose half-life, V(d), and clearance were 30 days, 143 mL/kg, and 4 mL/kg/day, respectively. HIVIG rapidly cleared maternal serum immune complex-dissociated p24 antigen, and plasma HIV-1 RNA levels were stable. Mild to moderate adverse clinical effects occurred in 2 of 103 maternal and 2 of 25 infant infusions. No adverse hematologic, blood chemistry, or immunologic effects were seen. HIVIG is well-tolerated in HIV-infected pregnant women and their newborns, clears antigenemia, crosses the placenta, and exhibits pharmacokinetics similar to those of other immunoglobulin preparations.

AB - The pharmacokinetics and safety of hyperimmune anti-human immunodeficiency virus (HIV) intravenous immunoglobulin (HIVIG) were evaluated in the first 28 maternal-infant pairs enrolled in a randomized, intravenous immunoglobulin (IVIG)-controlled trial of HIVIG maternal-infant HIV transmission prophylaxis. Using 200 mg/kg, mean half-life and volume of distribution (V(d)) in women were 15 days and 72 mL/kg, respectively, after one and 32 days and 154 mL/kg after three monthly infusions, with stable 4 mL/kg/day clearance. Transplacental passage occurred. Newborn single-dose half-life, V(d), and clearance were 30 days, 143 mL/kg, and 4 mL/kg/day, respectively. HIVIG rapidly cleared maternal serum immune complex-dissociated p24 antigen, and plasma HIV-1 RNA levels were stable. Mild to moderate adverse clinical effects occurred in 2 of 103 maternal and 2 of 25 infant infusions. No adverse hematologic, blood chemistry, or immunologic effects were seen. HIVIG is well-tolerated in HIV-infected pregnant women and their newborns, clears antigenemia, crosses the placenta, and exhibits pharmacokinetics similar to those of other immunoglobulin preparations.

UR - http://www.scopus.com/inward/record.url?scp=17344391461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17344391461&partnerID=8YFLogxK

U2 - 10.1093/infdis/175.2.283

DO - 10.1093/infdis/175.2.283

M3 - Article

C2 - 9203648

AN - SCOPUS:17344391461

VL - 175

SP - 283

EP - 291

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -